{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28subcutaneous%29",
    "query": {
      "intervention": "Placebo (subcutaneous)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 2222,
    "total_pages": 223,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28subcutaneous%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-20T22:54:36.497Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00135720",
      "title": "Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pemphigus Vulgaris"
      ],
      "interventions": [
        {
          "name": "Enbrel (Etanercept)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2004-06",
      "completion_date": "2007-11",
      "has_results": false,
      "last_update_posted_date": "2015-06-03",
      "last_synced_at": "2026-09-20T22:54:36.497Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00135720"
    },
    {
      "nct_id": "NCT00712673",
      "title": "GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Lixisenatide (AVE0010)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pen auto-injector",
          "type": "DEVICE"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 680,
      "start_date": "2008-06",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2016-12-15",
      "last_synced_at": "2026-09-20T22:54:36.497Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00712673"
    },
    {
      "nct_id": "NCT04172441",
      "title": "Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Congenital Hyperinsulinism"
      ],
      "interventions": [
        {
          "name": "dasiglucagon",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zealand Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Days",
        "maximum_age": "364 Days",
        "sex": "ALL",
        "summary": "7 Days to 364 Days"
      },
      "enrollment_count": 12,
      "start_date": "2020-06-19",
      "completion_date": "2022-03-07",
      "has_results": true,
      "last_update_posted_date": "2025-03-14",
      "last_synced_at": "2026-09-20T22:54:36.497Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Fort Worth, Texas",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04172441"
    },
    {
      "nct_id": "NCT05131477",
      "title": "Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Eczema",
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Amlitelimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kymab Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 390,
      "start_date": "2021-12-13",
      "completion_date": "2024-02-21",
      "has_results": true,
      "last_update_posted_date": "2025-07-03",
      "last_synced_at": "2026-09-20T22:54:36.497Z",
      "location_count": 20,
      "location_summary": "Fremont, California • Sacramento, California • Boca Raton, Florida + 16 more",
      "locations": [
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05131477"
    },
    {
      "nct_id": "NCT07773727",
      "title": "A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immunoglobulin A Nephropathy (IgAN)"
      ],
      "interventions": [
        {
          "name": "ARGX-121",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2026-10-15",
      "completion_date": "2030-02-18",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-09-20T22:54:36.497Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Manassas, Virginia",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Manassas",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07773727"
    },
    {
      "nct_id": "NCT00604786",
      "title": "The Effect of Omalizumab on Responses to Cat Allergen Challenge",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "omalizumab",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 18,
      "start_date": "2007-07",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2017-05-10",
      "last_synced_at": "2026-09-20T22:54:36.497Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00604786"
    },
    {
      "nct_id": "NCT00267969",
      "title": "A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "ustekinumab",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centocor Research & Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 766,
      "start_date": "2005-12",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2013-06-17",
      "last_synced_at": "2026-09-20T22:54:36.497Z",
      "location_count": 28,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Redwood City, California + 25 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00267969"
    },
    {
      "nct_id": "NCT04492475",
      "title": "Adaptive COVID-19 Treatment Trial 3 (ACTT-3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Interferon beta-1a",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Remdesivir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 969,
      "start_date": "2020-08-05",
      "completion_date": "2020-12-21",
      "has_results": true,
      "last_update_posted_date": "2022-03-14",
      "last_synced_at": "2026-09-20T22:54:36.497Z",
      "location_count": 55,
      "location_summary": "Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04492475"
    },
    {
      "nct_id": "NCT05552157",
      "title": "A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Alzheimers Disease",
        "Dementia",
        "Alzheimers Disease, Familial"
      ],
      "interventions": [
        {
          "name": "Remternetug (SC)",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo (Remternetug)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 280,
      "start_date": "2024-11-22",
      "completion_date": "2034-08-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-09-20T22:54:36.497Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05552157"
    },
    {
      "nct_id": "NCT01343966",
      "title": "A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "MABT5102A",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 448,
      "start_date": "2011-04-30",
      "completion_date": "2014-02-28",
      "has_results": false,
      "last_update_posted_date": "2017-07-12",
      "last_synced_at": "2026-09-20T22:54:36.497Z",
      "location_count": 40,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Encino, California + 36 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01343966"
    }
  ]
}